WILLOW GROVE, Pa.--(BUSINESS WIRE)--In an announcement last week, the U.S. Drug Enforcement Administration (DEA) placed the synthetic cannabinoid, MAB–CHMINACA (also known as ADB–CHMINACA), into Schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act.

WILKES-BARRE — When Les Stark of the Keystone Cannabis Coalition organized a rally in Wilkes-Barre last year, he was excited at the prospect of new state laws on medical cannabis and industrial hemp.

He’s still waiting, but the status of marijuana in Pennsylvania may be changing. Several bills are moving through the state Legislature. Stark, of Exeter Township in Berks County, is confident that when he organizes an event next year in the city, medical cannabis and farmed hemp will be legal in the state.

One unexpected benefit of medical marijuana legislation appears to be a decrease in painkiller overdoses, perhaps because some chronic pain patients are turning to cannabis instead of powerful opioid drugs.

In states with laws legalizing medical marijuana, new research shows there are nearly 25 percent fewer deaths from painkiller overdoses. Opioid painkiller overdoses are a growing problem nationwide. More than 16,500 Americans died of opioid drug overdoses in 2010, and the numbers continue to rise.

Although a casual relationship hasn’t been proven, there appears to be a significant association between marijuana legislation and a fall in overdose deaths.

PHILADELPHIA You still can't say "marijuana" in the head shop.

For years, the stores that sell marijuana pipes and bongs have insisted that the products they sell are for tobacco use, choosing their words carefully to avoid being ensnared in laws against marijuana paraphernalia.

As states and cities across the country have lowered the penalties for possession, a patchwork of federal, state and local laws means little has changed at the head shops.

“The map of the United States is colorful as to where you can lawfully buy paraphernalia and not use magic code words,” said Allen St. Pierre, executive director of the National Organization for the Reform of Marijuana Laws.

PITTSBURGH — In room 716 of the Children's Hospital of Pittsburgh, 12-year-old Hannah Pallas is motionless, but for an occasional turn of her head and blink of her eyes, following a series of life-threatening seizures. On the same day, 5-year-old Sydney Michaels is down the hall in room 749, waiting to be discharged after 15 grand mal seizures within 36 hours.

Their mothers have known each other for years, though it's a hapless coincidence caused by their daughters' epilepsy that brings them to the pediatric unit on the same day.

We all know that Wiz Khalifa smokes a lot of cannabis. But just how much?

We also know that Snoop Dogg smokes a lot of cannabis too – around 75 to 80 blunts a day to be exact. But just how do these two hip-hop artist and marijuana enthusiasts compare for their consumption?

Jimmy Kimmel talks with Wiz about his latest album, Blacc Hollywood, while also finding out how often Wiz Khalifa smokes.

Are you surprised by Wiz Khalifa’s answers? We’re guessing not. Watch below!

A popular argument against legalization of marijuana is that evidence shows teen marijuana use may lead to mood disorders like depression in later life, but new research suggests that the link may not exist or at least may not be as pronounced as we might have feared.

Pennsylvania drugmaker Zynerba Pharmaceuticals ($ZYNE) is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.

The company priced 3 million shares at $14 each, the middle of its range, and set aside another 450,000 shares for its underwriters to line up for as much as $51.8 million in total.

Devon, PA, August 4, 2015 – Zynerba Pharmaceuticals, Inc., announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba’s common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol “ZYNE” on August 5, 2015.